Author(s):
Neeraj Kumar, Ashok Kumar Gupta
Email(s):
ashokg195@gmail.com
DOI:
10.52711/0974-360X.2025.00639 
Address:
Neeraj Kumar1,2, Ashok Kumar Gupta3*
1National Institute of Pharmaceutical Education and Research (NIPER), Hajipur - 844102, India.
2Galgotias College of Pharmacy, Knowledge Park - 2, Greater Noida, U.P., 201310, India.
3School of Pharmacy, Sharda University, Knowledge Park - 3, Greater Noida, U.P., 201306, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 9,
Year - 2025
ABSTRACT:
Background: Gemcitabine-Cisplatin combination chemotherapy regimen is the standard treatment for advanced gallbladder cancer (GBC); however, the Paclitaxel-Cisplatin regimen is rarely preferred. Limited clinical studies have reported the hematological and nephrotoxic effects of Gemcitabine versus Paclitaxel based chemotherapy in combination with Cisplatin. Materials and Methods: A total of 55 patients with GBC participated in this prospective observational study. All patients had cytologically confirmed gallbladder cancer. The patients were divided into two study groups, i.e. Group A (n=32) patients received Gemcitabine-Cisplatin and in Group B (n=23) patients received Paclitaxel-Cisplatin based chemotherapy regimen. All the patients of both groups were examined for their hematological and renal parameters up to the fourth cycle of chemotherapy. Results: Significant changes observed in hematological, renal parameters as well as in malondialdehyde level (p < 0.05) from baseline, compared after fourth cycle of chemotherapy in both treatment groups. After comparison in between Group A and Group B, significant differences were observed in hematological (red blood cell, platelets and hemoglobin), renal (Urea and Creatinine) and malondialdehyde level after fourth cycle of chemotherapy (p < 0.05). Conclusion: These findings indicate that, after the fourth chemotherapy cycle, the Gemcitabine-Cisplatin regimen observed with less and comparatively manageable nephrological and hematological toxicity compared to the Paclitaxel-Cisplatin regimen.
Cite this article:
Neeraj Kumar, Ashok Kumar Gupta. Comparative Study of the Toxicity Profile in Gallbladder Cancer patients receiving Gemcitabine-Cisplatin versus Paclitaxel-Cisplatin Combination Chemotherapy. Research Journal of Pharmacy and Technology. 2025;18(9):4455-0. doi: 10.52711/0974-360X.2025.00639
Cite(Electronic):
Neeraj Kumar, Ashok Kumar Gupta. Comparative Study of the Toxicity Profile in Gallbladder Cancer patients receiving Gemcitabine-Cisplatin versus Paclitaxel-Cisplatin Combination Chemotherapy. Research Journal of Pharmacy and Technology. 2025;18(9):4455-0. doi: 10.52711/0974-360X.2025.00639 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-9-59
REFERENCES:
1. Vaittinen E. Carcinoma of gallbladder: A study of 390 cases diagnosed in Finland 1953-1967. Ann Chir Gynaecol. 1970; 168: 1–81.
2. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996; 7: 593–600. doi: 10.1093/oxfordjournals.annonc.a010676.
3. Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis. 1986; 8: 356–67.
4. Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatin associated nephrotoxicity and pathological events. Contrib Nephrol. 2005; 148: 107–21. doi: 10.1159/000086055.
5. Srivastava RC, Farookh A, Ahmad N, Misra M, Hasan SK, Husain MM. Reduction of cisplatinum-induced nephrotoxicity by zinc histidine complex: The possible implication of nitric oxide. Biochem Mol Biol Int. 1995; 36: 855–62.
6. Crinò L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol. 1997; 15: 297–303. doi: 10.1200/JCO.1997.15.1.297.
7. Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602–8. doi: 10.1200/JCO.2005.07.757.
8. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008; 61: 903–9. doi: 10.1007/s00280-007-0574-5.
9. Khan EA, Misra M, Sharma P, Misra AN. Effects of exogenous nitric oxide on protein, proline, MDA contents, and antioxidative system in pea seedlings (Pisum sativum L.). Res J Pharm Tech. 2017; 10(9): 3137–42. doi: 10.5958/0974-360X.2017.00555.5.
10. Bae S, Pan XC, Kim SY, Park K, Kim YH, Kim H, et al. Exposures to particulate matter and polycyclic aromatic hydrocarbons and oxidative stress in school children. Environ Health Perspect. 2010; 118: 579–83. doi: 10.1289/ehp.0901079.
11. Esterbauer H, Eckl P, Ortner A. Possible mutagens derived from lipids and lipid precursors. Mutat Res. 1990; 238: 223–33. doi: 10.1016/0165-1110(90)90014-3.
12. Yang X, Zheng J, Bai Y, Tian F, Yuan J, Sun J, et al. Using lymphocyte and plasma Hsp70 as biomarkers for assessing coke oven exposure among steel workers. Environ Health Perspect. 2007;115:1573–7. doi: 10.1289/ehp.10283.
13. Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillimoe KD, Shulick R, et al. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol. 2003; 163: 217–29. doi: 10.1016/S0002-9440(10)63650-7.
14. Tannapfel A, Sommerer F, Benicke M, Katalinik A, Uhlmann D, Witzigmann H, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003; 52: 706–12. doi: 10.1136/gut.52.5.706.
15. Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008; 98: 485–9. doi: 10.1002/jso.21009.
16. Kayahara M, Nagakawa T. Recent trends of gallbladder cancer in Japan: An analysis of 4,770 patients. Cancer. 2007; 110: 572–80. doi: 10.1002/cncr.22806.
17. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity: A review. Cancer Chemother Pharmacol. 1989; 25: 1–9. doi: 10.1007/BF00685649.
18. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother. 1993; 27: 1519–25. doi: 10.1177/106002809302701209.
19. Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M. Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury. J Pharmacol Sci. 2006; 100: 65–72. doi: 10.1254/jphs.FPJ05037X.
20. Hardevinder P, Singh TG, Singh R. Attenuation of cisplatin-induced nephrotoxicity by p-coumaric acid through peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonism in male rats. Res J Pharm Tech. 2020; 13(11): 5270–6. doi: 10.5958/0974-360X.2020.00924.9.
21. Reham T, Jwaid AH. The possible protective effect of Daflon 500mg on cisplatin-induced nephrotoxicity in experimental rats. Res J Pharm Tech. 2023; 16(7): 3393–8. doi: 10.5958/0974-360X.2023.00599.0.
22. Andre T, Louvet C, Artru P, Selle F, Turnigand C, Garcia ML, et al. A phase II study of gemcitabine and oxaliplatin (GEMOX) in advanced biliary adenocarcinoma (ABA). Preliminary results. Eur J Cancer. 2001; 37: 19. doi: 10.1016/S0959-8049(01)80255-9.
23. Abhirama BR, Rajagopal SS, Nanjan M. Nephroprotective effect of ethanol extract of Biophytum sensitivum (Linn.) DC in cisplatin-induced experimental renal damage in rats. Res J Pharm Tech. 2017; 10(6): 1772–9. doi: 10.5958/0974-360X.2017.00312.4.
24. Murad AM, Guimara RC, Aragao BC, Rodrigues VH, Scalabrini-Neto AO, Padua CA, et al. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol. 2003; 26(2): 151–4. doi: 10.1097/00000421-200304000-00008.
25. Salama ZA, Aboul-Enein AM, Gaafar AA, Asker MS, Aly HF, Ahmed HA. In-vitro antioxidant, antimicrobial and anticancer activities of banana leaves (Musa acuminata) and olive leaves (Olea europaea L.) as by-products. Res J Pharm Tech. 2020; 13(2): 687–96. doi: 10.5958/0974-360X.2020.00125.7.
26. Abdulazeem L, AL Jassani MJ, Al-Sheakh MA. Free radical scavenging and antioxidant activity of silver nanoparticles synthesized from Cuminum cyminum (cumin) seed extract. Res J Pharm Tech. 2021; 14(8): 4349–54. doi: 10.5958/0974-360X.2021.00755.5.
27. Doval DC, Sekhon JS, Gupta SK, Gupta S, Awasthy BS. Chemotherapy in biliary tract carcinomas: results in India. Semin Oncol. 2002; 29: 46–50. doi: 10.1053/sonc.2002.31526.
28. Malik IA, Aziz Z, Zaidi SHM. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gall bladder. Am J Clin Oncol. 2003; 26(2): 174–7. doi: 10.1097/01.COC.0000051888.22878.45.
29. Lichtman SM. Chemotherapy in the elderly. Semin Oncol. 2004; 31: 160–74. doi: 10.1053/j.seminoncol.2003.12.030.
30. Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068–77. doi: 10.1200/JCO.2000.18.17.3068.
31. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996; 2: 521–30.
32. Seena KX, Setty MM. Protective effect of phytochemicals against cisplatin-induced nephrotoxicity. Res J Pharm Tech. 2021; 14(7): 3981–6. doi: 10.5958/0974-360X.2021.00695.0.
33. Mugada VK, Hanumanthu J, Shagufa J, Iype S, Yerlapati S. Assessment of ototoxicity and nephrotoxicity in patients receiving weekly cisplatin chemotherapy: A prospective observational study. Res J Pharm Tech. 2019; 12(4): 1922–6. doi: 10.5958/0974-360X.2019.00323.0.
34. Crinò L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol. 1997; 15: 297–303. doi: 10.1200/JCO.1997.15.1.297.
35. Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602–8. doi: 10.1200/JCO.2005.07.757.
36. Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, et al. Advanced biliary tract carcinomas: A retrospective multicenter analysis of first and second-line chemotherapy. BMC Gastroenterol. 2014; 14: 143. doi: 10.1186/1471-230X-14-143.
37. Umamahesvari H. Fabrication and character study of the anticancer drug paclitaxel (Taxol): PLGA nanoparticles - The benefaction for the modern therapeutic area. Res J Pharm Tech. 2020; 13(1): 265–9. doi: 10.5958/0974-360X.2020.00048.7.
38. Zhang D, Sun L, Xian W, Liu F, Ling G, Xiao L, et al. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab Invest. 2010; 90: 436–47. doi: 10.1038/labinvest.2010.8.
39. Zhou J, Zhong DW, Wang QW, Miao XY, Xu XD. Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity. World J Gastroenterol. 2010; 16: 3330–4. doi: 10.3748/wjg.v16.i26.3330.
40. Nainggolan SI, Rajuddin R, Hasanuddin H, Keumalazia R, Hambal M, Frengki F. In silico analysis of anticancer curcumin and its metabolites in increasing the effectiveness of paclitaxel. Res J Pharm Tech. 2023; 16(2): 885–2. doi: 10.5958/0974-360X.2023.00152.6.